These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28326832)

  • 1. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.
    Popat S; Mellemgaard A; Reck M; Hastedt C; Griebsch I
    Future Oncol; 2017 Jun; 13(13):1159-1171. PubMed ID: 28326832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
    Dhillon S
    Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.
    Popat S; Mellemgaard A; Fahrbach K; Martin A; Rizzo M; Kaiser R; Griebsch I; Reck M
    Future Oncol; 2015; 11(3):409-20. PubMed ID: 25478720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
    Reck M; Syrigos K; Miliauskas S; Zöchbauer-Müller S; Fischer JR; Buchner H; Kitzing T; Kaiser R; Radonjic D; Kerr K
    Lung Cancer; 2020 Oct; 148():159-165. PubMed ID: 32927350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
    Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
    Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
    Reck M; Mellemgaard A; von Pawel J; Gottfried M; Bondarenko I; Cheng Y; Zarogoulidis K; Luft A; Bennouna J; Barrueco J; Aboshady H; Hocke J; Kaiser R; Douillard JY;
    Lung Cancer; 2015 Nov; 90(2):267-73. PubMed ID: 26415992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis Inhibitors in NSCLC.
    Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
    Espinosa Bosch M; Asensi Diez R; García Agudo S; Clopes Estela A
    Farm Hosp; 2016 Jun; 40(4):316-27. PubMed ID: 27571499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
    Gottfried M; Bennouna J; Bondarenko I; Douillard JY; Heigener DF; Krzakowski M; Mellemgaard A; Novello S; Orlov S; Summers Y; von Pawel J; Stöhr J; Kaiser R; Reck M
    Target Oncol; 2017 Aug; 12(4):475-485. PubMed ID: 28702806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
    Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
    Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer.
    Novello S; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Barrueco J; Gaschler-Markefski B; Griebsch I; Palmer M; Reck M;
    Eur J Cancer; 2015 Feb; 51(3):317-26. PubMed ID: 25534294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
    Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
    N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
    Hanna NH; Kaiser R; Sullivan RN; Aren OR; Ahn MJ; Tiangco B; Voccia I; Pawel JV; Kovcin V; Agulnik J; Gaschler-Markefski B; Barrueco J; Sikken P; Schloss C; Kim JH;
    Lung Cancer; 2016 Dec; 102():65-73. PubMed ID: 27987591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
    Reck M; Heigener D; Reinmuth N
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):579-90. PubMed ID: 25119062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
    Syrios J; Nintos G; Georgoulias V
    Expert Rev Anticancer Ther; 2015; 15(8):875-84. PubMed ID: 26204906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
    Vickers AD; Winfree KB; Cuyun Carter G; Kiiskinen U; Jen MH; Stull D; Kaye JA; Carbone DP
    BMC Cancer; 2019 Apr; 19(1):353. PubMed ID: 30987609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
    Shiono A; Kaira K; Mouri A; Yamaguchi O; Hashimoto K; Uchida T; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):775-781. PubMed ID: 30809973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib plus docetaxel after progression on immune checkpoint inhibitor therapy: insights from VARGADO, a prospective study in patients with lung adenocarcinoma.
    Grohé C; Gleiber W; Haas S; Losem C; Mueller-Huesmann H; Schulze M; Franke C; Basara N; Atz J; Kaiser R
    Future Oncol; 2019 Aug; 15(23):2699-2706. PubMed ID: 31282758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.